Benefits
Plant-Based EPA Source (Bioavailable)
The Stiefvatter 2021 RCT (n=22 healthy adults, 2 weeks) showed PT biomass at 5.3 g/day produced similar plasma EPA increases and n-6:n-3 ratio reductions to fish oil with equivalent EPA+DHA content. Establishes PT as a genuine bioavailable EPA source — relevant for vegetarians, vegans, and sustainability-minded consumers.
Fucoxanthin Bioavailability
PT consumption increased plasma fucoxanthin and metabolites (fucoxanthinol, amarouciaxanthin A) — confirming oral bioavailability of the carotenoid. Plasma β-carotene also increased. Fucoxanthin has documented preclinical activity for body fat reduction, antioxidation, and cholesterol regulation.
Healthy Aging Support (Pilot Data)
The Stiefvatter 2022 randomized controlled pilot trial in elderly individuals tested EPA/Fx-rich PT biomass and chrysolaminarin-rich (β-glucan) PT supernatant. Suggested potentially beneficial effects on inflammageing and metabolic markers. Pilot-stage evidence; not yet definitive.
Sustainable Omega-3 Source
Microalgae are the original primary producers of EPA in marine food chains — fish accumulate it from algae. Direct microalga supplementation bypasses fish entirely, addressing concerns about overfishing, mercury/PCB contamination, and dietary preferences (vegetarian/vegan). Environmental sustainability is a major driver of PT interest.
Possible Gut Microbiome Effects
Mouse studies (Stiefvatter 2022) showed PT diet increased colonic SCFA production and decreased Firmicutes/Bacteriodota ratio. Chrysolaminarin-rich diets specifically increased Akkermansia (a beneficial gut bacterium). Human translation is preliminary; mechanism is plausible given the β-glucan content.
Mechanism of action
EPA Provision and n-3:n-6 Ratio Modulation
PT contains ~3-5% EPA by dry weight in EPA-rich growth conditions. Oral PT consumption raises plasma EPA and reduces the n-6:n-3 ratio — the same metabolic effects as fish oil. EPA is the precursor to anti-inflammatory eicosanoids (prostaglandin E3, leukotriene B5) and resolvin/protectin specialized pro-resolving mediators.
Fucoxanthin Antioxidant and Anti-Adipogenic Activity
Fucoxanthin is a unique xanthophyll carotenoid found in brown algae and diatoms. It scavenges free radicals, may reduce plasma and liver triglycerides, and shows anti-adipogenic effects in animal models (UCP1 induction in white adipose tissue). Fucoxanthinol (its main metabolite) retains bioactivity.
Chrysolaminarin (β-1,3-Glucan) Prebiotic / Immune Effects
Chrysolaminarin is a β-1,3-glucan storage polysaccharide unique to chrysophyte and diatom algae. β-Glucans modulate immune function via dectin-1 receptor binding on innate immune cells and serve as prebiotic substrates. Animal studies show increased Akkermansia muciniphila with chrysolaminarin-rich diets.
Sustainable Feedstock with Concentrated Nutrients
PT is photoautotrophic — grows on CO2 + light + minimal nutrients. This makes it a sustainable source of nutrients without the trophic accumulation of pollutants (mercury, dioxins) found in fatty fish. Cultivation conditions can be tuned to produce EPA/fucoxanthin-rich or chrysolaminarin-rich biomass.
Multi-Nutrient Synergy
Beyond individual bioactives, PT provides simultaneous EPA, fucoxanthin, β-glucans, protein, and minor nutrients. The combination may produce effects beyond what isolated EPA or fucoxanthin can achieve — though this synergy claim awaits direct RCT confirmation.
Clinical trials
Randomized intervention trial with crossover design. 5.3 g/day whole PT biomass vs. fish oil (300 mg combined EPA+DHA) for 2 weeks each. Additional arm: 185 g/week sea fish in 9 individuals. Outcomes: plasma fatty acids, fucoxanthin, fucoxanthinol, amarouciaxanthin A, β-carotene, safety parameters. (Stiefvatter, Lehnert, Frick, Montoya-Arroyo, Frank, Vetter, Schmid-Staiger, Bischoff 2021, Mar Drugs)
22 healthy young adults (intent-to-treat); 9 in fish sub-arm.
PT consumption produced similar plasma n-3 PUFA and EPA increases and similar n-6:n-3 ratio decreases as fish oil with equivalent EPA+DHA content. Plasma fucoxanthin and metabolites confirmed bioavailability. β-carotene also increased. NO relevant adverse effects. Authors concluded PT is a safe and effective EPA + fucoxanthin source — future sustainable food option.
Randomized controlled pilot trial in elderly individuals. Three test supplements based on PT biomass A (EPA/fucoxanthin-rich, nutrient-replete growth) and supernatant B (chrysolaminarin/β-glucan-rich, nutrient-depleted growth). Outcomes: omega-3 status, inflammageing markers, intestinal barrier indicators. (Stiefvatter, Frick, Lehnert, Schäfer, Bischoff 2022, Mar Drugs)
Elderly individuals aged 60-90 years.
Suggested potentially beneficial effects on healthy aging via EPA-rich PT and chrysolaminarin-rich supernatant supplementation. Pilot data demonstrating feasibility, safety, and bioavailability in elderly population. Effect sizes preliminary; calls for larger confirmatory trials.
About this ingredient
Phaeodactylum tricornutum is a marine diatom microalga of growing commercial interest as a sustainable nutritional source. It contains substantial EPA (eicosapentaenoic acid, 3-5% by dry weight in EPA-rich strains), fucoxanthin (a brown-colored xanthophyll carotenoid unique to brown algae and diatoms), chrysolaminarin (β-1,3-glucan storage polysaccharide), high-quality protein (30-40%), and other minor nutrients. Cultivation conditions can be tuned to produce different nutrient profiles: nutrient-replete conditions yield EPA/fucoxanthin-rich biomass, while nutrient-depleted conditions yield chrysolaminarin-rich biomass.
EVIDENCE: Stiefvatter 2021 establishes EPA and fucoxanthin bioavailability comparable to fish oil for EPA. Stiefvatter 2022 pilot suggests healthy-aging benefits in elderly. Most evidence is bioavailability/feasibility; long-term clinical outcome data is still emerging.
Mechanism (EPA, fucoxanthin, β-glucan) is well-characterized from broader literature on those individual bioactives. SAFETY: Excellent in published trials. Sustainable, non-fish source of EPA appealing for vegetarians/vegans and sustainability-conscious consumers.
NOT yet a substitute for proven fish oil/algal oil omega-3 supplements with extensive clinical evidence base — represents an emerging next-generation alternative.